34 min listen
Fighting Blindness & Funding The Fight With Opus Genetics' CEO Ben Yerxa, Ph.D.
Fighting Blindness & Funding The Fight With Opus Genetics' CEO Ben Yerxa, Ph.D.
ratings:
Length:
46 minutes
Released:
Apr 25, 2022
Format:
Podcast episode
Description
Opus Genetics is an early-stage gene therapy company launched just last year and in unique fashion on the back of the patient advocacy group the Retinal Degeneration Fund. Already, its pipeline has developed into three candidates, the lead among them addressing Leber congenital amaurosis. Opus CEO Ben Yerxa, Ph.D. serves in triplicate as CEO at the RD Fund, Foundation Fighting Blindness, and Opus Genetics. His plate is full, but he's a man on a mission. On this episode of the Business of Biotech, Dr. Yerxa shares his story, that of Opus Genetics' unique approach to addressing inherited retinal diseases, and how the company is addressing current development and capacity challenges in the cell & gene manufacturing space.
Released:
Apr 25, 2022
Format:
Podcast episode
Titles in the series (100)
Summer Sessions 6: Alexis Peyroles On Myeloid Cells, Transplants, & Immuno-Oncology Inspiration by Business Of Biotech